Drugs Made In America Acquisition Corp. Files 8-K
Ticker: DMAAR · Form: 8-K · Filed: Feb 4, 2025 · CIK: 2028614
| Field | Detail |
|---|---|
| Company | Drugs Made In America Acquisition Corp. (DMAAR) |
| Form Type | 8-K |
| Filed Date | Feb 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $10.00, $200,000,000, $4,000,000, $1,100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, filing, corporate-event
TL;DR
DMAA filed an 8-K on Jan 29th, check it out.
AI Summary
Drugs Made In America Acquisition Corp. filed an 8-K on February 4, 2025, reporting an event that occurred on January 29, 2025. The filing pertains to "Other Events" and "Financial Statements and Exhibits." The company is incorporated in the Cayman Islands and its principal executive offices are located in Fort Lauderdale, FL.
Why It Matters
This filing indicates a corporate event or financial update for Drugs Made In America Acquisition Corp., requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without immediate indication of significant financial distress or major corporate changes.
Key Numbers
- 001-42467 — SEC File Number (Identifies the company's filing history with the SEC.)
- 25588360 — Film Number (Internal SEC processing number for the filing.)
Key Players & Entities
- Drugs Made In America Acquisition Corp. (company) — Registrant
- Cayman Islands (jurisdiction) — Place of incorporation
- Fort Lauderdale, FL (location) — Principal Executive Offices
- January 29, 2025 (date) — Date of earliest event reported
- February 4, 2025 (date) — Filing date
FAQ
What specific 'Other Events' are being reported by Drugs Made In America Acquisition Corp. in this 8-K?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of the 'Financial Statements and Exhibits' being filed?
This suggests that the company is providing updated financial information or relevant supporting documents as part of this report.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on January 29, 2025.
What is the company's principal executive office address?
The principal executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301.
What is the SIC code for Drugs Made In America Acquisition Corp.?
The Standard Industrial Classification (SIC) code is 6770, which corresponds to 'BLANK CHECKS'.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 12.2 · Accepted 2025-02-04 16:15:03
Key Financial Figures
- $0.0001 — isting of one Ordinary Share, par value $0.0001 per share, and one Right to receive one
- $10.00 — tion. The Units were sold at a price of $10.00 per Unit, generating aggregate gross pr
- $200,000,000 — regate gross proceeds to the Company of $200,000,000. Simultaneously with the closing of t
- $4,000,000 — nits at a price of $10.00 per unit, for $4,000,000, of which $1,100,000 has not yet been r
- $1,100,000 — 0.00 per unit, for $4,000,000, of which $1,100,000 has not yet been received and is accoun
- $201,000,000 — t. As of January 29, 2025, a total of $201,000,000 of the net proceeds from the IPO and th
Filing Documents
- ea0229853-8k_drugs.htm (8-K) — 33KB
- ea022985301ex99-1_drugs.htm (EX-99.1) — 135KB
- 0001213900-25-010079.txt ( ) — 168KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 4, 2025 DRUGS MADE IN AMERICA ACQUISITION CORP. By: /s/ Lynn Stockwell Name: Lynn Stockwell Title: Chief Executive Officer 2